FcIII peptide

FcIII peptide conjugated with fluorescein (50 nM; 0-2.5 g/L human IgG) binds strongly to purified human IgG, increasing the dynamic range of fluorescence polarization by 260 mP, with a half-maximal response concentration of 0.001 g/L^[1].
FcIII peptide conjugated with fluorescein increases by up to 2.1-fold in 0.01-100 g/L hydroxypropyl-β-cyclodextrin systems, a result that confirms the fluorescence enhancement induced by IgG binding is driven by a hydrophobic microenvironment. Unlabeled SpA binds specifically to this peptide in a competitive manner, and 500 nM SpA reduces the fluorescence intensity of the FcIII peptide-human IgG complex to the background level of the free peptide^[1].
FcIII peptide conjugated with fluorescein modulates the linear quantitative range for fluorescence intensity detection of human IgG while maintaining a stable fluorescence polarization response^[1].
FcIII peptide conjugated with fluorescein (100 nM; 0-2.5 g/L IgG) detects human IgG and adalimumab biosimilars in serum-free CHO-S cell culture medium^[1].
FcIII peptide potently inhibits the binding between the Z domain of Protein A and human IgG Fc, with a K_i value of 25 nM at pH 7.2^[2].
FcIII peptide uses Val-10 and Trp-11 as key residues for binding to human IgG Fc^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.